CRISPR/$CRSP
1D1W1MYTD1Y5YMAX
Capital at risk
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- Ticker
- $CRSP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 393
- Headquarters
- Zug, Switzerland
- Website
- www.crisprtx.com
CRISPR Metrics
BasicAdvanced
$5.2B
-
-$4.76
1.76
-
Price and volume
Market cap
$5.2B
Beta
1.76
52-week high
$78.48
52-week low
$44.12
Average daily volume
1.7M
Financial strength
Current ratio
17.847
Quick ratio
17.791
Long term debt to equity
0.438
Total debt to equity
0.449
Profitability
EBITDA (TTM)
-513.174
Gross margin (TTM)
-3,448.33%
Net profit margin (TTM)
-3,368.72%
Operating margin (TTM)
-3,971.53%
Effective tax rate (TTM)
-0.68%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-14.20%
Return on equity (TTM)
-26.09%
Valuation
Price to revenue (TTM)
382.952
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-13.72
Free cash flow yield (TTM)
-7.29%
Free cash flow per share (TTM)
-3.942
Growth
Revenue change (TTM)
-64.80%
Earnings per share change (TTM)
-12.57%
3-year revenue growth (CAGR)
-57.14%
10-year revenue growth (CAGR)
24.32%
3-year earnings per share growth (CAGR)
-3.51%
10-year earnings per share growth (CAGR)
-5.09%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Analyst projections of the future price of CRISPR stock.
Bulls say / Bears say
CASGEVY is showing a stronger commercial trajectory, with quarterly sales of about $76 million and more than 100 patient initiations; the FDA’s expansion to children aged two and over broadens the addressable population. Management says earlier reimbursement, hospital contracting and manufacturing bottlenecks have largely eased. (CRISPR Therapeutics, Transcript Daily)
CTX310 produced durable one-year reductions of roughly 50% in LDL cholesterol and triglycerides after a single infusion in a 15-person Phase 1 study, with no serious treatment-related adverse events reported. This is early evidence, but it supports CRSP’s strategy of developing one-off in-vivo gene-editing treatments for cardiovascular disease. (Cleveland Clinic, CRISPR Therapeutics)
The pipeline offers several potential value-creating catalysts beyond CASGEVY: management expects CTX310, zugo-cel and CTX611 could reach pivotal or Phase 3 development next year, while further data are due across cardiovascular, autoimmune and oncology programmes. CRSP’s roughly $2.36 billion cash, cash equivalents and marketable securities provide time to fund these programmes. (CRISPR Therapeutics, Quartr)
CASGEVY’s headline product sales do not translate directly into CRSP revenue: the company shares economics with Vertex and reported only about $10 million of collaboration revenue against a $91 million quarterly net loss. That makes the investment case dependent on a sustained ramp rather than the product’s gross sales alone. (EveryTicker, Motley Fool)
CRSP remains heavily loss-making and cash-burning while it expands several clinical programmes. The company ended June with about $2.36 billion in liquidity, but first-half operating cash use was about $192 million and its $600 million convertible-note issue creates future dilution risk. (CRISPR Therapeutics, NAI 500)
The strongest pipeline evidence is still early-stage: the CTX310 result came from only 15 patients and showed biomarker changes, not proof of fewer cardiovascular events. Other important assets such as zugo-cel remain in Phase 1/2, so safety, durability and efficacy could still fail to translate into pivotal-trial success or approval. (Cleveland Clinic, CRISPR Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRISPR News
AllArticlesVideos
Funds containing CRISPR
AllEURUSDGBP
Fund name | Fund size | $CRSP weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.46% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.35% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.35% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.16% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.